Bristol-Myers Squibb (BMY) Stock Price, Quote, News & History

Comments

Bristol-Myers Squibb Co (BMY) Stock Price, Quote, News & History

BMYNYSE

Trade with Public

$58.06

-0.56-0.96%

At close: Apr 10, 5:00 PM EST

$58.14

-0.48-0.82%

Pre-Market: 4:56 AM EST

OverviewNews Earnings Options Guidance Dividends Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Key Statistics

Open

-

Close

$58.06

Volume / Avg.

240.00 / 13.11M

Day Range

- - -

52 Wk Range

42.52 - 62.89

Market Cap

$118.71B

P/E Ratio

16.78

Dividend Yield

4.34%

Exchange

NYSE

RSI

45

Short Interest

1.54%

Days to Cover

1.99

Recent Bristol-Myers Squibb Co News

FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short

FDA says Replimmune melanoma therapy lacks sufficient efficacy evidence, citing trial flaws and limited data in BLA resubmission review.

Vandana Singh

MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst

Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.

Vandana Singh

Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma

FDA approves Opdivo combo by Bristol Myers Squibb for untreated Hodgkin Lymphoma, showing improved progression-free survival.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

14.16B

Investing Cash Flow (TTM)

-4.13B

Financing Cash Flow (TTM)

-10.35B

Free Cash Flow (TTM)

12.85B

Capital Expenditure (TTM)

-1.31B

Net Change in Cash (TTM)

-324.00M

Analyst Trends and Forecast

3

2

Jan

3

2

Feb

0

Mar

2

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.8

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$155.01B

PE Ratio (TTM)

16.78

PE Ratio (FWD)

9.29

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.46

PB Ratio (TTM)

6.42

Earnings Yield % (TTM)

5.96%

Earnings Yield % (FWD)

10.76%

EV / EBITDA (TTM)

10.18

Price / EBITDA (TTM)

7.77

Price / Free Cash Flow (TTM)

9.22

Book Value / Share

$9.05

Company Debt

Total Debt

$45.11B

LT Debt

$42.85B

LT Debt Issuance (TTM)

$5.74B

LT Debt Repayment (TTM)

-$10.94B

Total Cash

$10.21B

Debt to Equity

2.55

Issuance of Debt (TTM)

-$5.20B

Repayment of Debt (TTM)

-$10.94B

Key Statistics

Open

-

Close

$58.06

Volume / Avg.

240.00 / 13.11M

Day Range

- - -

52 Wk Range

42.52 - 62.89

Market Cap

$118.71B

P/E Ratio

16.78

Dividend Yield

4.34%

Exchange

NYSE

RSI

45

Short Interest

1.54%

Days to Cover

1.99

About

Sector

Health Care

Industry

Pharmaceuticals

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol deriv...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Bristol-Myers Squibb (BMY) stock?

A

You can purchase shares of Bristol-Myers Squibb (NYSE:BMY) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Bristol-Myers Squibb (BMY) competitors?

A

Other companies in Bristol-Myers Squibb’s space includes: Novo Nordisk AS (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and Terns Pharmaceuticals Inc (NASDAQ:TERN).

Q

What is the forecast, or price target, for Bristol-Myers Squibb (BMY) stock?

A

Bristol-Myers Squibb has a consensus price target of $61.75.

Q

What is the current price for Bristol-Myers Squibb (BMY)?

A

The stock price for Bristol-Myers Squibb (NYSE: BMY) is $58.14 last updated April 14, 2026 at 4:23 AM EDT.

Q

Does Bristol-Myers Squibb (BMY) pay a dividend?

A

There are no upcoming dividends for Bristol-Myers Squibb.

Q

When is Bristol-Myers Squibb (NYSE:BMY) reporting earnings?

A

Bristol-Myers Squibb does not have any upcoming earnings scheduled.

Q

Is Bristol-Myers Squibb (BMY) going to split?

A

There is no upcoming split for Bristol-Myers Squibb.

Q

What sector and industry does Bristol-Myers Squibb (BMY) operate in?

A

Bristol-Myers Squibb is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.

People Also Watch

Terns Pharmaceuticals Inc

Axsome Therapeutics Inc

NASDAQ:AXSM

$178.33

%

Key Statistics

Open

-

Close

$58.06

Volume / Avg.

240.00 / 13.11M

Day Range

- - -

52 Wk Range

42.52 - 62.89

Market Cap

$118.71B

P/E Ratio

16.78

Dividend Yield

4.34%

Exchange

NYSE

RSI

45

Short Interest

1.54%

Days to Cover

1.99

Recent Bristol-Myers Squibb Co News

FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short

FDA says Replimmune melanoma therapy lacks sufficient efficacy evidence, citing trial flaws and limited data in BLA resubmission review.

Vandana Singh

MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst

Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.

Vandana Singh

Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma

FDA approves Opdivo combo by Bristol Myers Squibb for untreated Hodgkin Lymphoma, showing improved progression-free survival.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

14.16B

Investing Cash Flow (TTM)

-4.13B

Financing Cash Flow (TTM)

-10.35B

Free Cash Flow (TTM)

12.85B

Capital Expenditure (TTM)

-1.31B

Net Change in Cash (TTM)

-324.00M

Analyst Trends and Forecast

3

2

Jan

3

2

Feb

0

Mar

2

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.8

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$155.01B

PE Ratio (TTM)

16.78

PE Ratio (FWD)

9.29

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.46

PB Ratio (TTM)

6.42

Earnings Yield % (TTM)

5.96%

Earnings Yield % (FWD)

10.76%

EV / EBITDA (TTM)

10.18

Price / EBITDA (TTM)

7.77

Price / Free Cash Flow (TTM)

9.22

Book Value / Share

$9.05

Company Debt

Total Debt

$45.11B

LT Debt

$42.85B

LT Debt Issuance (TTM)

$5.74B

LT Debt Repayment (TTM)

-$10.94B

Total Cash

$10.21B

Debt to Equity

2.55

Issuance of Debt (TTM)

-$5.20B

Repayment of Debt (TTM)

-$10.94B

Key Statistics

Open

-

Close

$58.06

Volume / Avg.

240.00 / 13.11M

Day Range

- - -

52 Wk Range

42.52 - 62.89

Market Cap

$118.71B

P/E Ratio

16.78

Dividend Yield

4.34%

Exchange

NYSE

RSI

45

Short Interest

1.54%

Days to Cover

1.99

About

Sector

Health Care

Industry

Pharmaceuticals

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol deriv...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry